logo
Scientists Recreated the Universe's First Molecule

Scientists Recreated the Universe's First Molecule

Gizmodo16 hours ago
Seconds after the Big Bang, the newborn universe gave rise to the first elements—ionized forms of hydrogen and helium. These particles combined, forging helium hydride—the first ever molecule. It would take another several hundred million years for the first stars to be born, and scientists have long puzzled over the exact nature of the chemical processes that led to their formation.
To try and tease apart the stellar origin story, scientists at the Max Planck Institute for Nuclear Physics in Heidelberg, Germany recreated helium hydride in the lab. They found that it likely played a much larger role in star birth than they had previously thought, helping primordial gas clouds shed enough heat to collapse into stars.
In the study, the researchers recreated collisions between helium hydride and deuterium in what they believe to be a first-of-its-kind experiment, according to a press release. Their findings, published in the journal Astronomy & Astrophysics on July 24, indicate that the rate of the reaction remains constant as the temperature drops, contradicting earlier work.
'Previous theories predicted a significant decrease in the reaction probability at low temperatures, but we were unable to verify this in either the experiment or new theoretical calculations by our colleagues,' Holger Kreckel, who is a researcher at Max Planck and the lead author on the study, said in a statement.
'The reactions of [helium hydride] with neutral hydrogen and deuterium therefore appear to have been far more important for chemistry in the early universe than previously assumed,' he added.
Two helium hydride reactions produce molecular hydrogen, and likely aided star formation in the early universe. In the first—replicated in the study—deuterium, an isotope of hydrogen that contains a neutron in addition to a proton, collides with helium hydride to yield hydrogen deuteride, a form of molecular hydrogen composed of a hydrogen atom and a deuterium atom. The other reaction occurs when helium hydride collides with a neutral hydrogen atom, producing neutral molecular hydrogen. Both forms of molecular hydrogen act as coolants, helping nebulae lose heat, condense, and ultimately collapse into stars.
The researchers used Max Planck's Cryogenic Storage Ring to carry out their experiment. This low-temperature reaction chamber allows scientists to study molecular and atomic reactions in space-like conditions. The team stored helium hydride ions inside the chamber for up to a minute at roughly -450 degrees Fahrenheit (-267 degrees Celsius), then superimposed them with a beam of neutral deuterium atoms. To observe how the collision rate varies with collision energy—directly related to temperature—they adjusted the relative speeds of the two particle beams.
Scientists previously believed rate of reactions would slow down as temperature dropped, but the results of this experiment suggest otherwise. The researchers found that the rate remained almost constant despite decreasing temperatures. This surprising result suggests that helium hydride remains chemically active even in cold conditions, a finding that the scientists argue in their paper should prompt a reevaluation of helium chemistry in the early universe.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Purespring Therapeutics receives UK CTA approval for Phase I/II clinical trial of PS-002 in patients with primary IgA nephropathy (IgAN)
Purespring Therapeutics receives UK CTA approval for Phase I/II clinical trial of PS-002 in patients with primary IgA nephropathy (IgAN)

Yahoo

time30 minutes ago

  • Yahoo

Purespring Therapeutics receives UK CTA approval for Phase I/II clinical trial of PS-002 in patients with primary IgA nephropathy (IgAN)

First patient in Phase I/II clinical trial expected to be enrolled in Q4 2025 UK Clinical Trial Application (CTA) approval shortly follows U.S. IND clearance and granting of European Medicine Agency (EMA) orphan drug designation, enabling readiness for initiation across sites in both the U.S. and Europe PS-002, Purespring's lead precision nephrology programme, targets the complement pathway known to be a driver of IgA nephropathy and is supported by a wealth of preclinical data London – 5 August 2025 - Purespring Therapeutics, a precision nephrology company focused on transforming the treatment of kidney diseases, today announces that its UK Clinical Trial Application (CTA) for a planned Phase I/II study of PS-002, Purespring's lead programme, in patients with IgA nephropathy (IgAN) has been approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA), the NHS Health Research Authority (HRA) and Research Ethics Committee (REC). 'The CTA approval for our Phase I/II clinical trial of PS-002 represents another key milestone as we complete our transition to a clinical-stage precision nephrology company,' said Haseeb Ahmad, Purespring's Chief Executive Officer. 'Building on the recent FDA IND clearance and EMA orphan drug designation, this further validates the potential of our podocyte-targeting approach to go beyond symptom management and directly target kidney disease at its source. Looking ahead, we are committed to working closely with regulators and sites across the U.S. and Europe with the view to expand the therapeutic options available for people living with IgAN.' PS-002 was developed to target the underlying cause of many kidney diseases by modulating complement activation in the kidney via precision targeting of podocytes. The programme is initially focused on the treatment of IgA nephropathy (IgAN), a rare and chronic autoimmune kidney disease that primarily affects young adults. In IgAN, aberrant immunoglobin A (IgA) protein becomes trapped in the kidney's filters, known as the glomeruli, causing complement activation, inflammation, damage and scarring. A significant proportion of affected patients will go on to develop kidney failure despite currently available therapies. The Phase I/II clinical trial, which is expected to enroll its first patient in Q4 2025, will evaluate local administration of PS-002 to treat IgAN. In the Phase 1 part of the Phase I/II study, the main read-outs will be safety parameters, which, together with efficacy biomarkers, will be leveraged to select a dose for the Phase 2 part of the study. This second phase will be used to further define the safety profile and provide early markers of efficacy. Enabled by this latest regulatory approval and the recent U.S. IND clearance, as announced in July 2025, the Phase I/II study will recruit patients across the U.S. and Europe. For further information, contact: Purespring: Peter Mulcahycontact@ (0)20 3855 6324LinkedIn ICR Healthcare Amber Fennell, Sarah Elton-Farrpurespring@ Notes to Editors About Purespring Purespring is developing therapies to halt or prevent kidney disease, one of humankind's most poorly treated disease areas. Founded on the work of Professor Moin Saleem, Professor of Paediatric Renal Medicine at the University of Bristol, Purespring is the first company to successfully treat kidney disease by targeting the podocyte, a specialised cell that is implicated in the majority of renal disease. Purespring's platform approach enables streamlined gene therapy development for both acquired and genetic renal diseases, offering the potential to halt, reverse and even cure both rare and common kidney diseases. The Company currently has a pipeline of programmes in development including the lead asset for treatment of IgA Nephropathy (IgAN) and other complement mediated kidney disease. The Company also has programmes for disease caused by mutations in the gene NPHS2, as well as other monogenic glomerular kidney diseases. Based in London, the Purespring team combines world-leading expertise in podocyte biology and kidney disease with a wealth of experience in gene therapies, anchored in a culture of diversity, creativity and delivery. Purespring is backed by leading biotech investors, including Syncona Limited, Sofinnova Partners, Gilde Healthcare, Forbion, and the British Business Bank and has raised £115m ($149m) to date. For more information please visit: and follow us on in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Aicuris Presents Pharmacokinetic Data from the First-in-Human Clinical Trial of AIC468, a Novel Antisense Oligonucleotide Targeting BK Virus, at World Transplant Congress
Aicuris Presents Pharmacokinetic Data from the First-in-Human Clinical Trial of AIC468, a Novel Antisense Oligonucleotide Targeting BK Virus, at World Transplant Congress

Associated Press

time2 hours ago

  • Associated Press

Aicuris Presents Pharmacokinetic Data from the First-in-Human Clinical Trial of AIC468, a Novel Antisense Oligonucleotide Targeting BK Virus, at World Transplant Congress

Wuppertal, Germany, August 5, 2025 - Aicuris Anti-infective Cures AG today announced initial clinical data from its ongoing first-in-human Phase 1 trial with AIC468. The novel antiviral antisense oligonucleotide is in development for the treatment of BK virus (BKV) infections in kidney transplant recipients. The interim results, presented at the World Transplant Congress in San Francisco on August 4, 2025, provide an overview of PK characteristics of AIC468 from the Phase 1 clinical trial in healthy volunteers. 'BK virus infections represent a serious and persistent threat for immunocompromised patients with a high risk of renal damage or kidney loss after transplantation. The PK results and safety data to date are very encouraging and provide us with valuable insights for the continued development of this differentiated program,' said Cynthia Wat, MD, CMO of Aicuris. 'Our goal is to achieve tangible therapeutic solutions for immunocompromised patients with kidney transplants, and these strong PK and safety data are an important step for us in achieving this goal.' FIH trial data from 72 healthy volunteer subjects, six single ascending dose (SAD) subcutaneous cohorts, one intravenous dose level and two multiple ascending dose (MAD) subcutaneous cohorts were presented at World Transplant Congress. AIC468 was safe and well tolerated across all cohorts investigated to date. The product candidate achieved excellent bioavailability (82%), rapid absorption, and distribution to peripheral tissues. A favorable half-life together with pre-clinical data, suggests that efficacious kidney concentrations can be attained by weekly or less frequent dosing regimens within the investigated dose range. Additionally, renal clearance for AIC468 accounted for less than 2% of the total clearance, representing a negligible route of elimination. Tissue uptake and subsequent metabolism appear to be the primary route of clearance, supporting the observed benign safety profile. The trial is progressing as planned in the third MAD cohort. 'Aicuris continues to build momentum by executing on our clinical trial strategy and achieving the first positive data set for our third clinical program for immunocompromised patients,' added Larry Edwards, CEO of Aicuris. 'In the second half of 2025 we expect data from the Phase 1 program to allow us to rapidly advance AIC468 into a Phase 2a proof-of-mechanism trial in H1 2026 to demonstrate its value for patients.' The randomized, double-blind, placebo-controlled first-in-human trial ( 2023-510074-13-00 ) is designed to evaluate the safety, tolerability and pharmacokinetics of AIC468 in healthy volunteers. SAD cohorts tested AIC468 or a placebo control in a total of 56 healthy volunteers across six subcutaneous (25 mg to 600 mg) and one intravenous dose level (200 mg). In the MAD cohorts an additional 24 subjects receive five repeated doses of AIC468 (130 mg, 230mg and 330 mg). Dosing in all SAD and the first two MAD cohorts have been successfully completed. The trial is progressing as planned in the third MAD cohort with data expected later this year. About BKV BKV is a ubiquitous polyomavirus that infects most people in early childhood, typically without symptoms. In immunocompromised individuals, such as organ transplant recipients, BKV can reactivate, leading to serious health issues. In kidney transplant patients, BKV reactivation can cause BK virus-associated nephropathy (BKVAN), affecting up to 10% of recipients and potentially resulting in graft loss. Current management involves reducing immunosuppressive therapy, which increases the risk of graft rejection. Despite its prevalence, there is no approved antiviral treatment specifically for BKV. About AIC468 AIC468 is an antisense oligonucleotide therapy designed to treat BK virus reactivation in kidney transplant patients which can pose a significant health risk for these patients. The candidate blocks viral replication within infected cells by inhibiting splicing of the pre-mRNA that encodes for the virus' large T-antigen. This innovative approach has already demonstrated potent antiviral activity along with a favorable pharmacokinetic and safety profile in preclinical studies and is currently being evaluated in a Phase 1 clinical trial. About Aicuris Aicuris is meeting the needs of the growing population of immunocompromised people who require precise therapies to effectively treat infection. Our flagship product, PREVYMIS®, marketed by our partner MSD, prevents CMV in a defined group of transplant recipients. Our pivotal Phase 3 candidate, pritelivir, aims to address refractory HSV infections in a broad population of patients with weakened immune systems. For immunocompromised people, an otherwise manageable infection can mean life or death. Aicuris, with its expertise and growing pipeline, is committed to providing therapeutic solutions for them now and in the future. Contact: Aicuris Anti-infective Cures AG [email protected] Trophic Communications Dr. Stephanie May and Dr. Charlotte Spitz Phone: +49 171 3512733 Email: [email protected]

How Supercomputing Will Evolve, According to Jack Dongarra
How Supercomputing Will Evolve, According to Jack Dongarra

WIRED

time3 hours ago

  • WIRED

How Supercomputing Will Evolve, According to Jack Dongarra

Aug 5, 2025 5:00 AM WIRED talked with one of the most influential voices in computer science about the potential for AI and quantum to supercharge supercomputers. Jack Dongarra in Lindau in July 2025. Photograph: Patrick Kunkel/Lindau Nobel Laureate Meetings High-performance supercomputing—once the exclusive domain of scientific research—is now a strategic resource for training increasingly complex artificial intelligence models. This convergence of AI and HPC is redefining not only these technologies, but also the ways in which knowledge is produced, and takes a strategic position in the global landscape. To discuss how HPC is evolving, in July WIRED caught up with Jack Dongarra, a US computer scientist who has been a key contributor to the development of HPC software over the past four decades—so much so that in 2021 he earned the prestigious Turing Award. The meeting took place at the 74th Nobel Laureate Meeting in Lindau, Germany, which brought together dozens of Nobel laureates as well as more than 600 emerging scientists from around the world. This interview has been edited for length and clarity. Jack Dongarra on stage at the 74th Lindau Nobel Laureate Meetings. Photograph: Patrick Kunkel/Lindau Nobel Laureate Meetings WIRED: What will be the role of artificial intelligence and quantum computing in scientific and technological development in the coming years? Jack Dongarra: I would say AI is already playing an important role in how science is done: We're using AI in many ways to help with scientific discovery. It's being used in terms of computing and helping us to approximate how things behave. So I think of AI as a way to get an approximation, and then maybe refine the approximation with the traditional techniques. Today we have traditional techniques for modeling and simulation, and those are run on computers. If you have a very demanding problem, then you would turn to a supercomputer to understand how to compute the solution. AI is going to make that faster, better, more efficient. AI is also going to have an impact beyond science—it's going to be more important than the internet was when it arrived. It's going to be so pervasive in what we do. It's going to be used in so many ways that we haven't really discovered today. It's going to serve more of a purpose than the internet has played in the past 15, 20 years. Quantum computing is interesting. It's really a wonderful area for research, but my feeling is we have a long way to go. Today we have examples of quantum computers—hardware always arrives before software—but those examples are very primitive. With a digital computer, we think of doing a computation and getting an answer. The quantum computer is instead going to give us a probability distribution of where the answer is, and you're going to make a number of, we'll call it runs on the quantum computer, and it'll give you a number of potential solutions to the problem, but it's not going to give you the answer. So it's going to be different. With quantum computing, are we caught in a moment of hype? I think unfortunately it's been oversold—there's too much hype associated with quantum. The result of that typically is that people will get all excited about it, and then it doesn't live up to any of the promises that were made, and then the excitement will collapse. We've seen this before: AI has gone through that cycle and has recovered. And now today AI is a real thing. People use it, it's productive, and it's going to serve a purpose for all of us in a very substantial way. I think quantum has to go through that winter, where people will be discouraged by it, they'll ignore it, and then there'll be some bright people who figure out how to use it and how to make it so that it is more competitive with traditional things. There are many issues that have to be worked out. Quantum computers are very easy to disturb. They're going to have a lot of 'faults'—they will break down because of the nature of how fragile the computation is. Until we can make things more resistant to those failures, it's not going to do quite the job that we hope that it can do. I don't think we'll ever have a laptop that's a quantum laptop. I may be wrong, but certainly I don't think it'll happen in my lifetime. Quantum computers also need quantum algorithms, and today we have very few algorithms that can effectively be run on a quantum computer. So quantum computing is at its infancy, and along with that the infrastructure that will use the quantum computer. So quantum algorithms, quantum software, the techniques that we have, all of those are very primitive. When can we expect—if ever—the transition from traditional to quantum systems? So today we have many supercomputing centers around the world, and they have very powerful computers. Those are digital computers. Sometimes the digital computer gets augmented with something to enhance performance—an accelerator. Today those accelerators are GPUs, graphics processing units. The GPU does something very well, and it just does that thing well, it's been architected to do that. In the old days, that was important for graphics; today we're refactoring that so that we can use a GPU to satisfy some of the computational needs that we have. In the future, I think that we will augment the CPU and the GPU with other devices. Perhaps quantum would be another device that we would add to that. Maybe it would be neuromorphic—computing that sort of imitates how our brain works. And then we have optical computers. So think of shining light and having that light interfere, and the interference basically is the computation you want it to do. Think of an optical computer that takes two beams of light, and in the light is encoded numbers, and when they interact in this computing device, it produces an output, which is the multiplication of those numbers. And that happens at the speed of light. So that's incredibly fast. So that's a device that perhaps could fit into this CPU, GPU, quantum, neuromorphic computer device. Those are all things that perhaps could combine. How is the current geopolitical competition—between China, the United States, and beyond—affecting the development and sharing of technology? The US is restricting computing at a certain level from going to China. Certain parts from Nvidia are no longer allowed to be sold there, for example. But they're sold to areas around China, and when I go visit Chinese colleagues and look at what they have in their their computers, they have a lot of Nvidia stuff. So there's an unofficial pathway. At the same time, China has pivoted from buying Western technology to investing in its own technology, putting more funding into the research necessary to advance it. Perhaps this restriction that's been imposed has backfired by causing China to accelerate the development of parts that they can control very much more than they could otherwise. The Chinese have also decided that information about their supercomputers should not be advertised. We do know about them—what they look like, and what their potential is, and what they've done—but there's no metric that allows us to benchmark and compare in a very controlled way how those computers compare against the machines that we have. They have very powerful machines that are probably equal to the power of the most significant machines that we have in the US. They're built on technology that was invented or designed in China. They've designed their own chips. They compete with the chips that we have in the computers that are in the West. And the question that people ask is: Where were the chips fabricated? Most chips used in the West are fabricated by the Taiwan Semiconductor Manufacturing Company. China has technology, which is a generation or two behind the technology that TSMC has, but they're going to catch up. My guess is that some of the Chinese chips are also fabricated in Taiwan. When I ask my Chinese friends 'Where were your chips manufactured?' they say China. And if I push them and say 'Well, were they manufactured in Taiwan?' the answer to that comes back eventually is Taiwan is part of China. Jack Dongarra on the shores of Lake Constance at the 74th Nobel Laureate Meeting. Photograph: Gianluca Dotti/Wired How will the role of programmers and developers change as AI evolves? Will we get to write software using only natural language? AI has a very important role I think in helping to take away some of the time-consuming parts of developing programs. It's gotten all the information about everybody else's programs that's available and then it synthesizes that and then can push that forward. I've been very impressed when I have asked some of these systems to write a piece of software to do a certain task; the AI does a pretty good job. And then I can refine that with another prompt, saying 'Optimize this for this kind of computer,' and it does a pretty good job of that. In the future, I think more and more we will be using language to describe a story to AI, and then have it write a program to carry out that function. Now of course, there are limits—and we have to be careful about hallucinations or something giving us the wrong results. But maybe we can build in some checks to verify the solutions that AI produces and we can use that as a way of measuring the potential accuracy of that solution. We should be aware of the potential problems, but I think we have to move ahead in this front. This story originally appeared on WIRED Italia and has been translated from Italian.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store